VRDN Stock Summary and Trading Ideas (Viridian Therapeutics | NASDAQ:VRDN)

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).

Viridian Therapeutics trades on the NASDAQ stock market under the symbol VRDN.

As of January 13, 2026, VRDN stock price declined to $31.99 with 1,222,183 million shares trading.

VRDN has a beta of 0.74, meaning it tends to be less sensitive to market movements. VRDN has a correlation of 0.07 to the broad based SPY ETF.

VRDN has a market cap of $3.05 billion. This is considered a Mid Cap stock.

Last quarter Viridian Therapeutics reported $70,570 in Revenue and -$.34 earnings per share. This fell short of revenue expectation by $-26 million and exceeded earnings estimates by $.55.

In the last 3 years, VRDN traded as high as $39.00 and as low as $9.90.

The top ETF exchange traded funds that VRDN belongs to (by Net Assets): VTI, IWM, XBI, VXF, IWO.

VRDN has outperformed the market in the last year with a price return of +75.8% while the SPY ETF gained +20.8%. VRDN has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +52.4% and +1.4%, respectively, while the SPY returned +6.5% and +0.9%, respectively.

VRDN support price is $31.79 and resistance is $33.35 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VRDN shares will trade within this expected range on the day.